Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma
- PMID: 38351389
- DOI: 10.1007/s00259-024-06643-8
Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma
Abstract
Background: Hodgkin lymphoma (HL) in pediatric populations has a high survival rate but poses risks for long-term morbidities. Although [18F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([18F]FDG PET) scans offer potential for improved risk stratification, the definitive prognostic value of quantitative [18F]FDG PET parameters remains unclear for pediatric HL.
Methods: A single-center, retrospective study included pediatric patients diagnosed with HL between 2016 and 2023 treated according to EuroNet-PHL-C1 and DAL/GPOH-HD protocols. Patients underwent baseline and interim PET/CT scans after two chemotherapy cycles. Event-free survival (EFS) was the primary endpoint, Deauville score was the secondary endpoint. Quantitative [18F]FDG PET parameters included SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) that were evaluated using two segmentation methods (SUV 2.5, 41% SUVmax). Survival outcomes were assessed using Cox regression analysis.
Results: A total of 115 patients (50 males, median age 14.2 years) were studied, with a median follow-up period of 35 months. During this period, 16 cases (13.9%) of relapse or progression were noted. Baseline and interim MTV 2.5, MTV 41%, TLG 2.5, and TLG 41%, along with interim SUVmax, were significantly associated with worse EFS and correlated with post-treatment Deauville scores. In multivariable analysis, interim MTV 2.5 > 0 ml (adj. hazard ratio, HR: 3.89, p = 0.009) and interim TLG 41% ≥ 30 g (adj. HR: 7.98, p = 0.006) were independent risk factors for EFS.
Conclusion: Baseline and interim [18F]FDG PET parameters can serve as significant prognostic indicators for EFS and treatment response in pediatric HL. These quantitative measures could enhance individualized, risk-adapted treatment strategies for children and adolescents with HL.
Keywords: Event-free survival; Metabolic tumor volume; Pediatric Hodgkin Lymphoma; Segmentation; Total lesion glycolysis; [18F]FDG PET.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Prognostic Impact of Quantitative Changes Between Baseline and Interim 18 F-FDG PET/CT in Pediatric Classic Hodgkin Lymphoma.Clin Nucl Med. 2025 Jul 1;50(7):e407-e416. doi: 10.1097/RLU.0000000000005874. Epub 2025 Mar 31. Clin Nucl Med. 2025. PMID: 40173294
-
Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.BMC Cancer. 2018 May 3;18(1):521. doi: 10.1186/s12885-018-4432-4. BMC Cancer. 2018. PMID: 29724189 Free PMC article. Clinical Trial.
-
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.Ann Hematol. 2020 Jun;99(6):1321-1330. doi: 10.1007/s00277-020-04039-w. Epub 2020 Apr 24. Ann Hematol. 2020. PMID: 32333153
-
Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.Medicine (Baltimore). 2017 Apr;96(17):e6721. doi: 10.1097/MD.0000000000006721. Medicine (Baltimore). 2017. PMID: 28445287 Free PMC article. Review.
-
Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis.Front Oncol. 2023 Jul 14;13:1208531. doi: 10.3389/fonc.2023.1208531. eCollection 2023. Front Oncol. 2023. PMID: 37519817 Free PMC article.
Cited by
-
Semiquantitative 2-[18F]FDG PET/CT-based parameters role in lymphoma.Front Med (Lausanne). 2024 Dec 18;11:1515040. doi: 10.3389/fmed.2024.1515040. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39744526 Free PMC article. Review.
-
Assessing the intracranial metabolic score as a novel prognostic tool in primary CNS lymphoma with end of induction-chemotherapy 18F-FDG PET/CT and PET/MR.Cancer Imaging. 2024 Nov 11;24(1):152. doi: 10.1186/s40644-024-00798-1. Cancer Imaging. 2024. PMID: 39529203 Free PMC article.
References
-
- Kahn JM, Pei Q, Friedman DL, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. Lancet Haematol. 2022;9:e49-57. https://doi.org/10.1016/S2352-3026(21)00349-5 . - DOI - PubMed - PMC
-
- Perez-Callejo D, Zurutuza L, Royuela A, et al. Long-term follow up of Hodgkin lymphoma. Oncotarget. 2018;9:11638–45. https://doi.org/10.18632/oncotarget.24392 . - DOI - PubMed - PMC
-
- Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol. 2019;187:39–48. https://doi.org/10.1111/bjh.16014 . - DOI - PubMed - PMC
-
- Van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015;175:1007–17. https://doi.org/10.1001/jamainternmed.2015.1180 . - DOI - PubMed
-
- Holmqvist AS, Chen Y, Berano Teh J, et al. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma—Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Cancer. 2019;125:1373–83. https://doi.org/10.1002/cncr.31807 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical